2017
3
2017-08-03 17:00:00
"Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceutical's Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Vincent Anzalone: Thank you. Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results for its fiscal 2017 third quarter ended June 30, 2017. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. Dr. Bruce Given our Chief Operating Officer and head of R&D will also be available during the Q&A portion of the call. Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including without limitation, those with respect to Arrowhead's goals, plans and strategies, are forward-looking statements. These include statements regarding our expectations around the development, safety and efficacy of our drug candidates, projected cash runway and expected future development activities. These statements represent management's current expectations and are inherently uncertain. Thus, actual results may differ materially. Arrowhead disclaims any intent and undertakes no duty to update any of the forward-looking statements discussed on today's call. You should refer to the discussions under risk factors in Arrowhead's annual report on Form 10-K and the Company's subsequent quarterly reports on Form 10-Q for additional matters to be considered in this regard including risks and other considerations that could cause actual results to vary from the presented expected results expressed in today's call. With that said, I would like to turn the call to Christopher Anzalone, President and CEO of the company. Chris?
Christopher Anzalone: Thanks, Vince. Good afternoon, everyone, thank you for joining us today. For the last quarter, we had focused on meeting the aggressive timelines we set internally for our development programs while continuing with disciplined cash management. We are excited about our new platforms, our lead drug candidates are progressing rapidly towards the clinic, and our partnership with Amgen continues to be highly productive. These are all important steps for us as a company and give us confidence to push forward with our new and diverse pipeline of RNAi therapeutics. Since we made the decision in November of 2016 to discontinue development of prior generation drugs ARC-520, ARC-521 and ARC-AAT that utilize the EX1 delivery vehicle, we have been quiet about data on our new platform and we grow our candidates that being built upon it. Our plan has been to hold an Analyst R&D Day, to provide comprehensive update about the technology and our lead programs. We think the most effective time to hold this event is when our data across multiple programs have sufficiently matured and when we are in reasonable proximity to file with the regulators to start first in human studies, we are just about there. The Analyst R&D Day is scheduled for Thursday September 14 in New York City. It will be held live so analysts and institutional investors can attend in person and there will also be a webcast so those not in attendance can listen in. That's just 42 days from now so for today's call, I want to talk about the event and what to expect from presentations. There will be two primary components. First, we will discuss our new base platform, then together with expert KOLs we will discuss the three most advanced programs in our pipeline in the clinical and treatment dynamics of the disease states those three programs will be addressing. Regarding the platform presentation, we will go over the general design and benefits of our new delivery platform that we call TRMs or Targeted RNA Molecules. Importantly, TRMs are proven capable of efficient delivery and knock down of target genes not just in liver but also in tissues outside the liver without the need for a reengineered endosomal escape component as we had in our prior generation technology. We plan on showing some example data, demonstrating the activities of three different TRMs each optimized for different uses. One, deliver TRM that we are using for several drug candidates. Two, the tumor targeted TRMs used in our ARO-HIP2 candidates delivered systematically. And three TRM targeted to non-liver non-tumor tissue that we will disclose at the event. We have always believed that for RNAi to achieve its full potential as an important new therapeutic modality, it must address diseases beyond the liver. Arrowhead is leading this expansion with TRMs targetable to new organ systems and it's as matured from goal to reality. We think this represents a giant leap forward for the field and we believe presents a host of new opportunities unique to Arrowhead. We will discuss the unifying characteristics and strategies behind TRMs that maximize target gene knock down and minimize off target exposure. We see TRMs as a powerful enabling solution for RNAi therapeutics against a wider universe of potential diseases that were previously not accessible with other approaches. During the next component of the Analyst Day, we will go through a pipeline update that includes data on three of our lead programs. This will include guidance on when we expect to file with the regulators to begin first in human studies. Those lead programs are ARO-AAT which is the second generation of therapeutic against the liver disease associated with Alpha-1 Antitrypsin deficiency, ARO-HPV, which is the third generation therapeutic against the chronic hepatitis B infection, and [ARO-A+B3], our previously undisclosed candidates designed to knock down production of apolipoprotein C3 or APO-CIII to reduce elevated plasma triglyceride levels which is an independent risk factor for cardiovascular diseases. We have officially nominated the ARO-HPV and ARO-AAT candidates and final IMD enabling steps including manufacturing and GLP toxicology studies are scheduled to begin shortly. Each update will include preclinical data, discussion of the unmet need and opportunity for a new or improved therapy and for ARO-AAT and ARO-HPV, a recap of some of the important things we learned in our prior development programs that are helping to inform the development path of these new product candidates. We think the insights we have made about HPV and Alpha-1 liver disease, we have sent real competitive and strategic advantages that enable us to move with speed and precision once the clinical programs begin. The final component of the Analyst Day will be discussions from key opinion leaders in each lead disease area about disease biology, epidemiology, unmet need, current therapies and how we can character [ph] our candidates could fit in to treatment landscape. They will each give a brief presentation and will also be available for Q&A when the presentations conclude. The KOLs currently schedule are Dr. Jeffrey Teckman from the St. Louis University School of Medicine for Alpha-1 liver disease, Dr. Stephen Locarnini, from Victorian Infectious Disease Reference Laboratory or HPV and Dr. Ira Goldberg from the NYU Line Going Medical Center for Cardiovascular Disease. The Analyst Day will be pack full of new information that we have been excited about for some time and we are eager to share it with you. But that will likely just be the beginning of our efforts to get the word out about the progress our R&D organization has made and continues to make. We have substantially more data that we can present during the event so intend to look for opportunities present additional data at appropriate medical meetings in the future as we will always done in the past. In addition, as more candidates using liver TRMs, tumor TRMs and new organ systems TRMs become further advanced, we intend to give updates and guidance when possible. With that overview, I'd now like to turn the call over to Ken Myszkowski, Arrowhead's Chief Financial Officer. Ken?
Ken Myszkowski: Thank you, Chris, and good afternoon everyone. As we reported today our net loss for the three months ended June 30, 2017 was $5.3 million or $0.7 per share based on 74.8 million weighted average shares outstanding. This compares with a net loss of $19.4 million or $0.32 per share based on 60 million weighted average shares outstanding for the three months ended June 30, 2016. Revenue for the three months ended June 30, 2017 was $9.4 million compared to $40,000 for the three months ended June 30, 2016. This increase is driven by the upfront payments we received from our collaboration agreements with Amgen and these payments will continue to be recognized as revenue over the next several quarters. Total operating expenses for the three months ended June 30, 2017 were $14.9 million compared with $19.4 million for the three months ended June 30, 2016. The decrease is driven by the discontinuation of the clinical trials related to our previous clinical candidates. Net cash used by operating activities during the three months ended June 30, 2017 was $10.4 million compared with cash used of $18.3 million during the three months ended June 30, 2016. Cash used in operating activities decreased as compared to last year due to lower spending related to clinical trial expenses. Turning to our balance sheet, our cash in short term investments totaled $75.1 million at June 30, 2017 compared to cash of $85.4 million at September 30, 2016. We've invested $36.8 million in short term corporate bonds that mature within the next 12 months. Our total cash in investment balances decreased $10.2 million as compared to our September 30, 2016 balance. Our cash burn was partially offset by the $30 million upfront payment and a $12.5 million equity investment from Amgen. Our common shares outstanding at June 30, 2017 were 74.8 million. With that, I'll turn the call back to Chris.
Christopher Anzalone: Thanks Tim. Thank you all for joining us today and I hope everyone can listen to the presentations at the Analyst R&D Day on September 14. We think our new TRM platform as it is today is the product of many important breakthroughs. It was made possible through years of work and the exploration of countless different technology platforms by talented ARO-AAT scientists who are focused on innovation. We feel that ARO-AAR has always been the high science RNAi company. And we think our presentations at the Analyst Day next month will continue to support that view. We are thrilled to share our progress and we hope that everyone will be as excited about ARO-AAT's future as we are. I would now like to open the call for questions. Operator?
Operator: Thank you. [Operator Instructions]. And our first question comes from Madhu Kumar with Chardan. You may proceed.
Unidentified Analyst: Hi this is Christine on for Madhu. One question on whether we can expect any clinical or preclinical presentations at the Liver Meeting?
Bruce Given: Hi, this is Bruce Given. We will probably do some late breaker submissions. And it's of course always up to be up to the reviewers whether or not they accept those although we've had a pretty good track record of getting them in. So, at this point I can't say for sure, but I wouldnâ€™t be surprised.
Operator: [Operator Instructions]. And we have no further questions at the moment. I would now like to turn the call back over to Mr. Chris, you may proceed, sir.
Christopher Anzalone: Thanks everyone. I look forward to seeing you and some of you after all at September 14th Analyst Day.
Operator: Thank you. Ladies and gentlemen, this does conclude the call. You may all disconnect. Everyone have a great day."
0.507
